Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …

Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved
Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Background: Patients with heart failure (HF) and reduced ejection fraction will experience
multiple hospitalizations for heart failure during the course of their disease. We assessed the …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background Patients recently hospitalized for heart failure (HF) are at high risk for
rehospitalization and death. Objectives The purpose of this study was to investigate clinical …

Importance In 2 trials enrolling patients with heart failure (HF) across the spectrum of
ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …

Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies …

Aims Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular
death among patients with heart failure with mildly reduced or preserved ejection fraction. In …